Tuesday, 9 October 2018

Palliative Care Market Pegged to Expand Robustly During 2018-2023

Market Scenario 
Increasing incidence of diseases such as cancer, cardiovascular and infective disease are some of the drivers responsible for the market growth of global palliative care market. Other factors such as a growing number of palliative care centers worldwide, expanding aging demographics, increasing number of qualified physicians for palliative care are responsible for the rise in the global palliative market. The main object of palliative care is to enhance personal satisfaction for both the patient and family. This palliative care can be provided at any age and at any phase in a genuine ailment and can be furnished alongside remedial treatment.
But the high cost of treatment, less private or public funding to hospital facilities and other medical centers can be a major restraint for the growth of the global palliative care market.
Global Palliative Care market is expected to grow during the forecast period (2018–2023) at a CAGR ~8.1 %.
Palliative care helps to improve the quality of life of patients and their families facing the problems of serious illness. The main focus of Palliative care is to provide relief from symptoms and stress of a serious illness. Their main goal is to improve the quality of life for both the patient and the family. Palliative care treats people living with a serious illness such as cancer, cardiac diseases such as congestive heath failure, kidney failure, Alzheimer’s and many more. It improves the quality of life of the patient and supports the primary physician, patient, and family. In last 15 years, the Palliative care market has a stunning growth and the factors that have led to the growth of this market are growing the aging population, increase in chronic life-threatening disease, initiative taken by the government and non- profit organization, and rise in government funding.  
However, the high cost of treatment, misuse of funding and lack of awareness are some of the factors which are hampering the growth of the market during the forecast period.
Segmentation
The Global Palliative Care Market is segmented into types such as private residence care, hospice inpatient care, hospital inpatient care, nursing home and residential facility care and others. On the basis of application, the market is further segmented into cancer, cardiac diseases such as congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), kidney failure, Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis (ALS) and many more. On basis of end-user, the market is further segmented into hospitals, home care settings, palliative care centers, long-term care centers & rehabilitation centers.
Key Players
·         Vitas Healthcare Corporation
·         Skilled Healthcare Group Incorporated
·         Sunrise Senior Living LLC
·         Kindred Healthcare Incorporated
·         Gentiva Health Services Incorporated
·         Home Instead Senior Care Incorporated
·         Amedisys Incorporated
·         Genesis HealthCare Corporation
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Global Palliative Care Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European Global Palliative Care Market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Global Palliative Care Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Palliative care market in the Middle East and Africa has been segmented into the Middle East and Africa.
In terms of market value, North America will dominate the Palliative care market during the forecast period. Increasing incidences of life-threatening illness such as cancer, cardiovascular diseases, Alzheimer’s disease, kidney failure, chronic obstructive pulmonary disease and many more are some of the factors which are responsible for the growth of the market during the forecast period. In 2015 on average 90 % of US hospitals containing 300 beds or more provide Palliative care services to their patients. This has led to the growth of the market in coming years. The European market is expected to be the second-largest Palliative care market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, a growing number of Palliative care centers worldwide, extending application for homecare, increasing number of qualified physicians for Palliative care center and expanding aging demographics are some of the factors responsible for the rise in the global Palliative care market. Asia-Pacific is expected to be the fastest-growing Palliative care market during the forecast period owing to the increasing prevalence of cardiac diseases, rising investments in healthcare, increasing geriatric population, and expansions by market players in the region. Asia-Pacific is giving the strong competition in the global Palliative care market by producing a cost-effective treatment that is high in demand in local as well as in the global market. The market in the Middle East and Africa is expected to account for the smallest share in the global Palliative care market due to the underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Table Of Content
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Mitochondrial Myopathies Market 2018: New Investment Opportunities Emerge to Widen Segments in Healthcare Industry by 2023

Market Synopsis of Global Mitochondrial Myopathies Market:
Market scenario:
Considering all these factors the market for mitochondrial myopathies is expected to reach $ 600 million by the end of 2023, this market is projected to growing at a CAGR of ~ 3.2 % during 2017-2023.
Mitochondrial myopathy is a rare mutational disease and at present there is no treatment available for the disease. However, there are few diagnostic tests available in the market which are the only saving grace for the global mitochondrial myopathy diagnosis and treatment market at present. Research play a major role in the determining new diagnostic test and treatment options for mitochondrial myopathy.

Increasing number of patients with mitochondrial myopathy patients, development in the disease screening process and testing services, availability of incentives for research in rare genetic diseases, and government funding and support for the development of the treatment options. However, the unavailability of treatment for rare genetic diseases, and lack of awareness about the diagnosis of these diseases are major factors restraining the growth of the market. Additionally, large portion of the population are underdiagnosed due to lack of diagnostic methods also hinders the growth of the market.


Key players of Global Mitochondrial myopathies Market:
·         Reata Pharmaceuticals, Inc.
·         Stealth BioTherapeutics
·         Raptor Pharmaceutical Corp.
·         GeneDx
·         NeuroVive Pharmaceutical AB
Segments:
The global mitochondrial myopathies market is segmented on the basis of type and therapies. Based on type, the market has been segmented as Kearns-Sayre syndrome (KSS), Leigh syndrome, Mitochondrial DNA depletion syndrome (MDS), Mitochondrial encephalomyopathy, Mitochondrial neuro-gastrointestinal encephalomyopathy (MNGIE), Myoclonus epilepsy with ragged red fibers (MERRF), Neuropathy, ataxia and retinitis pigmentosa (NARP), Pearson syndrome, Progressive external ophthalmoplegia (PEO). Based on the therapies, the market has been segmented as dietary, supportive, vitamins, coenzymes and antioxidants and other.
Regional analysis
US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is the fastest region because of large unmet needs which is led by China and India. The Middle East and Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa are expected to be a laggard due to poor economic and political conditions.
Detailed Table of Contents:
Table Of Contents
1. Introduction
1.1 Definition
1.2 Scope Of Study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.2.2.1 Assumptions
1.2.2.2 Limitations
1.3 Market Structure:
2. Research Methodology
2.1 Research Process:
2.2 Primary Research
2.3 Secondary Research:
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Macroeconomic Indicators
4. Market Factor Analysis
4.1 Porters Five Forces Model
4.2 Bargaining Power Of Suppliers
4.3 Bargaining Power Of Buyers
4.4 Threat Of New Entrants
4.5 Threat Of Substitutes
4.6 Intensity Of Rivalry

...Continued


         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Cerebral Palsy Market 2018: New Investment Opportunities Emerge to Widen Segments in Healthcare Industry by 2023

Market Scenario
Cerebral palsy (CP) is a congenital disorder that affects the muscle tone, movement, and motor skills. CP is generally considered to be caused by brain damage that happens before or during the baby's birth. The signs and symptoms of CP vary from person to person. According to the Centers for Disease Control and Prevention (CDC), some of the signs and symptoms of clinical palsy includes coordination and control problem, lack of muscle control, oral motor problems, and abnormal reflex responses. Currently, there are a wide variety of medications and therapies available to help people with cerebral palsy.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6334
The increasing prevalence of cerebral palsy coupled with increasing awareness about the condition is anticipated to drive the global cerebral palsy market. According to an article published by the National Center for Biotechnology Information (NCBI) in 2017, the overall birth prevalence of cerebral palsy is approximately 2 per 1,000 births worldwide. Moreover, the rising adoptions of medications for controlling the symptoms of the cerebral palsy are expected to boost the market growth. In addition, rising healthcare expenditure in developed economies and increasing insurance coverage contributes to the growth of the market during the assessment period. On the other hand, side effects associated with medications and high treatment cost and lack of awareness in some developing regions may hinder the growth of the market.
Despite the drivers, side effects associated with medications and high treatment cost and lack of awareness in some developing regions may hamper the market growth during the assessment period.
Segmentation
The global cerebral palsy market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into spastic cerebral palsy, dyskinetic cerebral palsy, hypotonic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy.
The market, by diagnosis, has been segmented into imaging tests and others. The imaging tests have been further segmented into magnetic resonance imaging (MRI), cranial ultrasound, computed tomography, and electroencephalogram.
The market, by treatment, has been segmented into therapy, medication, surgery, and others. The therapy segment has been segmented into nutrition therapy, hyperbaric oxygen therapy, occupational therapy, physical therapy, stem cell therapy, and others. The medication segment has been segmented into anti-convulsant drugs, muscle relaxants, anti-depressant drugs, anti-inflammatory drugs, and others. Further, the surgery segment has been segmented into orthopedic surgery and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The cerebral palsy market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European cerebral palsy market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The cerebral palsy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cerebral palsy market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players
Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc., Medtronic, Meridigen Biotech Co., Ltd., GW Pharmaceuticals Plc, and Cell Cure Neurosciences Ltd. are some of the key players in the global cerebral palsy market.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global cerebral palsy market owing to a well-developed healthcare sector, rising prevalence of cerebral palsy and growing healthcare expenditure. Additionally, favorable reimbursement scenario in this region and a relatively large number of research and development (R&D) activities contributes to the growth of the market.
Europe is expected to hold the second largest position in the global cerebral palsy market. The market growth in this region is attributed to the growing prevalence of cerebral palsy, availability of funds for research, and increasing healthcare expenditure. According to the data stated by the National Institute for Health and Care Excellence (NICE) in 2017, in the UK, it is estimated that 1 in 400 babies are born with cerebral palsy. It also stated that approximately 1,800 children diagnosed with CP each year.
The cerebral palsy market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of cerebral palsy and increasing government funding for the healthcare sector.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/6334   
Detailed Table of Contents:
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
List Of Tables and Figures
List Of Tables
Table 1 Global Cerebral Palsy Market Synopsis, 2018–2023
Table 2 Global Cerebral Palsy Market Estimates And Forecast, 2018–2023 (Usd Million)
Table 3 Global Cerebral Palsy Market, By Region, 2018–2023 (Usd Million)
Table 4 Global Cerebral Palsy Market, By Type, 2018–2023 (Usd Million)
Table 5 Global Cerebral Palsy Market, By Diagnosis, 2018–2023(Usd Million)
Table 6 Global Cerebral Palsy Market, By Treatment, 2018–2023 (Usd Million)
Table 7 North America: Cerebral Palsy Market, By Type, 2018–2023 (Usd Million)
List Of Figures
Figure 1 Research Process
Figure 2 Segmentation For Global Cerebral Palsy Market
Figure 3 Segmentation Market Dynamics For Global Cerebral Palsy Market
Figure 4 Global Cerebral Palsy Market Share, By Type, 2017
Figure 5 Global Cerebral Palsy Market Share, By Diagnosis, 2017
Figure 6 Global Cerebral Palsy Market Share, By Treatment, 2017
Figure 7 Global Cerebral Palsy Market Share, By Region, 2017
...Continued
Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/6334   

  
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Nausea Medicine Market 2018 Global Growth Opportunities, Key Driving Factors, Industry Scenario and Forecast to 2023

Market Synopsis of the Global Nausea Medicine Market
Nausea is a distress in stomach with involuntary urge to vomit which may be due to number of indications such as gastrointestinal diseases such as stomach upset, gastric ulcers. Furthermore, chemotherapy induced nausea is less common than other symptoms such as gastric reflux. Nausea is found to be common among children and pregnant women.
Rising prevalence of gastrointestinal diseases, such as Gastroesophageal Reflux Disease (GERD), and viral gastroenteritis, and availability of a wide range of treatment options drive the market growth. Furthermore, changing lifestyle and dietary habits also influence the market.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4523
Taste the market data and market information presented through more than 120 market data tables and figures spread over 200 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Nausea Medicine market research report–Global forecast till 2023.”
The global nausea medicine market is expected to grow at a CAGR of 7.2% during the forecast period.
Key Players in the Global Nausea Medicine Market     
Some of the key players in this market are Merck & Co., Inc. (U.S.), Sanofi (France), TESARO, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer (U.S.), GlaxoSmithKline (U.S.), ANI Pharmaceuticals, Inc. (U.S.).
Segments                                                                                                                                            
The global nausea medicine market is segmented on the basis of type, mode of administration, indication and end user.
On the basis of type, market is segmented into antacids, antagonists, anti-anxiety drugs, steroids, Cannabinoids and Others.
Antacids are further segmented into serotonin (5-HT3) antagonists, NK-1 antagonists and dopamine antagonists.
On the basis of mode of administration, the market is segmented into IVs, tablets and others.
On the basis of indication, the market is segmented into gastroesophageal reflux disease (GERD), viral gastroenteritis, motion sickness and seasickness, medication, chemotherapy and others.
On the basis of end user, the market is segmented into hospitals, clinics, pharmaceutical companies and others.
Regional Analysis of the Global Nausea Medicine Market                    
America rules the global nausea medicine market due to rising prevalence of nausea among pregnant women and children in the U.S and Latin America. Furthermore, availability of medicines for the treatment of nausea and rising awareness about the contraindications and safe use of medicines market also boost the market growth.

Europe acquires the second position in the market owing to rising prevalence of viral gastroenteritis. According to an article published in the journal of Clinical Virology, in Europe, acute infectious gastroenteritis is one of the major causes for substantial morbidity and economic loss.

Asia Pacific is the fastest growing market for nausea medicine due to lifestyle changes and unhealthy diet. Furthermore, prevalence of viral gastritis is also found to increasing. In Asia Pacific, the common cause of severe gastroenteritis in children less than 5 years of age, is rotavirus. The market in Asia Pacific is driven by an increasing demand for rapid diagnostics tests for gastrointestinal diseases and increasing awareness about available treatment options for viral gastroenteritis. Also, growing investments in the field of life science research and demand for advanced therapies for the treatment of nausea in developing nations such as China and India will propel the growth of the Asia Pacific market.

The market is Middle East & Africa is expected to show positive growth owing to an increase in the number of gastrointestinal problems such gastritis. Chemotherapy induced nausea is found to be prevalent in this region inducing the market growth.
Apply for Exclusive Discount  @ https://www.marketresearchfuture.com/check-discount/4523
In Asia Pacific, the market is expected grow at the fastest rate owing to changing lifestyle and increasing geriatric population fuel the market growth. Furthermore, viral gastritis and gastric ulcer are found to be prevalent among the Asian Population.  However, presence of misbranded and spurious drugs may restrain the market growth in Asia Pacific.
Detailed Table of Contents:
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/4523

      
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Global Nonallergic Rhinitis Market Trends, Demand and Forecast to 2023

Rising prevalence of nonallergic rhinitis, and increasing demand for diagnosis and treatment of nonallergic rhinitis are the major factors driving the growth of the market across the globe. Furthermore, increasing healthcare expenditure and overall growth of healthcare industry also influences the market growth. Splendid research in the field of immunology also boost the market. Additionally, increasing focus on the development of new medications for the treatment of nonallergic rhinitis, and increasing use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) also fuel the market growth.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5137
The Nonallergic Rhinitis Market growth of the market is restricted by increasing competition among key players in the market that act as a barrier of new entrants. The Global Nonallergic Rhinitis Market report is a professional in-depth analysis report which explores detail overview of some of the key players in this market which are Boehringer Ingelheim GmbH (Germany), Novartis (U.S.), GlaxoSmithKline (U.K), Perrigo Company plc (Ireland), Johnson & Johnson Consumer Inc. (U.S.), Bayer (U.S.), Sanofi (France) and others.
The global nonallergic rhinitis market is expected to grow at a CAGR of 5.3% during the forecast period.
Key Players in the Global Nonallergic Rhinitis Market
  • Boehringer Ingelheim GmbH (Germany)
  • Novartis (U.S.)
  • GlaxoSmithKline (U.K)
  • Perrigo Company plc (Ireland)
  • Johnson & Johnson Consumer Inc. (U.S.)
  • Bayer (U.S.)
  • Sanofi (France)
Regional Analysis of the Global Nonallergic Rhinitis Market               
America holds the first position in the market for nonallergic rhinitis owing to the rising prevalence of nonallergic rhinitis in the U.S., and consequent increase in the demand for new diagnostic and treatment services. In Americas, North America is the largest market owing to the presence of key players in the industry. As per the Warren Alpert Medical School of Brown University, the prevalence of nonallergic rhinitis has been observed to be one-third that of allergic rhinitis, affecting ~7% of the U.S. population or ~22 million people. Additionally, rising awareness about morbidity due to nonallergic rhinitis and the presence of key players in the market also influence the growth of the market.
Europe is the second largest market for nonallergic rhinitis. In Europe, there is an increasing demand for nasal sprays, and extensive research and development activities by clinical research and academic institutes for chronic diseases treatment. Germany, and France are the largest contributors to the market growth owing to an increase in the number of market players manufacturing NSAIDs, and overall growth of healthcare industry.
The market in Asia Pacific is expected to grow at the fastest pace and is driven by an increasing number of patients suffering from nonallergic rhinitis and increasing awareness about the diagnosis and treatment. India, China, and Japan are major contributors to the growth of the market. This growth is attributed to an increasing demand for nasal sprays and OTC medicines and availability of highly qualified medical personnel dedicated to the research of chronic diseases.
The Middle East & Africa also show a steady rise in the market owing to low prevalence of nonallergic rhinitis and increasing awareness about allergic and nonallergic rhinitis treatment. In the Middle East & Africa, the Middle East captures the largest market share for availability of specialty medical services and increasing expenditure on healthcare
Segments
The global nonallergic rhinitis market is segmented on the basis of diagnosis, treatment, and end user.
On the basis of diagnosis, market is categorized into physical examination, allergy testing, imaging test, and other segments. Allergy testing is further segmented into skin test and blood test. Imaging test is further segmented into nasal endoscopy, and computerized tomography (CT) Scan.
On the basis of treatment, the market is segmented into nasal sprays, NSAIDs and others.
Nasal sprays is further segmented into saline, corticosteroid, antihistamine, decongestants, and anti-drip anticholinergic.
On the basis of end user, the market is segmented into hospitals & clinics, research centers, and others.

Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/5137  
Detailed Table of Contents:
Table Of Contents
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
11 Appendix
Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/5137  

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Monday, 8 October 2018

Global Coma Diagnosis and Treatment Market 2018 Size, Status and Forecast to 2023

There is no particular treatment that can cause someone to come out of a coma and treatments can prevent further physical and neurological damage. However depending on the cause of a coma, patient who are continuosly in this state for more than one year are extremely unlikely to awaken.
Over the last decade, the number of hospitals has increased to a great extent, which has influenced the growth of the market positively. Moreover, increasing demand for better treatment and changing reimbursement policies have fueled the market growth.
Increasing prevalence of neurological disorders, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the market. Moreover, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases will fuel the market growth during the forecast period
According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.
However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.
The global coma diagnosis & treatment market is expected to grow at a CAGR of ~7.1% during the forecast period 2017-2023. 
Regional Analysis
The Americas dominate the global coma diagnosis & treatment market owing to well-developed technology, increasing patient population for brain disorder, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.
Europe holds the second position in the global coma diagnosis & treatment market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.     
Asia Pacific is the fastest growing coma diagnosis & treatment market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.  
On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Segmentations
The global coma diagnosis & treatment market is segmented on the basis of types, diagnosis, treatment, and end user.
On the basis of the type, it is segmented into toxic- metabolic encephalopathy, anoxic brain injury, persistent vegetative state, locked-in syndrome, and brain death.  
On the basis of diagnosis it is segmented into physical examination, blood test, brain scans, and others. Brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG).
On the basis of treatment it is segmented into medical treatment, and others.
On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.
Key Players
  • Fujifilm Holdings (Japan)
  • GE Healthcare (U.S.)
  • Siemens Healthcare(U.S.)
  • Philips Healthcare (U.S.)
  • Shimadzu Corporation (Japan)
  • Toshiba Medical Systems Corporation (Japan)
  • Carestream Health (U.S.)
  • Nihon Kohden Corporation (Japan)
  • Electrical Geodesics Inc. (U.S.)
  • Masimo Corporation (U.S.)
  • Hologic (U.S.)
  • Esaote (Italy)
Detailed Table of Contents:
1. Report Prologue
2. Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Mega Trends
4.5 Macroeconomic Indicators
5. Market Factor Analysis
5.1 Value Chain Analysis
5.2 Porters Five Forces
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
...Continued

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Optic Nerve Glioma Market 2018 World Analysis and Forecast to 2023

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Optic Nerve Glioma Market Research Report- Global Forecast till 2023” Gives industry size, top players and worldwide demand
Market Synopsis of Global Optic Nerve Glioma Market
Market scenario
Optic nerve glioma or optic glioma or juvenile pilocytic astrocytoma are types of brain tumour primarily affecting the optic nerve cells. Optic nerve gliomas are slow growing, rare and mostly found in children. Its occurrence in individuals over age 20 is quite rare and any occurrence is associated with the genetic disorder neurofibromatosis type 1, or NF1 in approximately 30% of the cases. Symptoms of an optic nerve glioma are nausea and vision disturbances, vomiting, balance problems, involuntary eye movements, memory impairment, delay in growth etc. ; daytime sleepiness is also witnessed in a large number of patients. The pressure exerted by these tumours may cause secondary effects such as hormonal problems due to effects on the pituitary gland. Optic nerve gliomas account for about 1% of all intracranial tumours. About 10% of optic nerve gliomas are located within an optic nerve, one third in both optic nerve and chiasm (left and right optic nerve crossing), and approximately one third involve the chiasm itself. The remaining one fourth optic nerve gliomas are in the hypothalamus and approximately 5 5% gliomas are multi-centric.
The treatment of optic nerve gliomas include surgery and radiation therapy. The drawbacks of surgery include high risk of brain damage and high costs. Surgery might not always be a good option due to location of the tumour. Radiation therapy for optic nerve gliomas has its own drawbacks such as damage to the eyes and brain, high costs and other side effects associated with its use such as vomiting, reduced immunity, hair loss etc. The primary aim of radiation therapy is to shrink the tumour and to kill any remaining cancer cells. Chemotherapy is used if the tumour has spread to other parts of the brain. Symptomatic and supportive treatment includes use of corticosteroids to reduce swelling etc. Most optic nerve gliomas are benign and malignant gliomas (glioblastoma) are rare and fatal.
The global optic nerve glioma market is expected to reach US$ 350 million by 2023, and the market is projected to grow at a CAGR of ~ 3.2 % during the forecast period 2017-2023.
Segments:
The global optic nerve glioma market has been segmented on the basis of types, diagnosis, treatment and end users.
Based on types, the market has been segmented as malignant optic nerve glioma and benign optic nerve glioma.
Based on the diagnosis, the market has been segmented into neurological exam, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), biopsy and others.
Based on the treatment, the market has been segmented into surgery, radiation therapy, chemotherapy and others.
Based on the end users, the market has been segmented as pharmace hospitals and clinics, diagnostic centers and others.
Regional analysis:
The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new technology in the US drives the global optic nerve glioma market. Also, concentration of major research companies and cancer research sector in the developed countries of this region is adding fuel to the market.
Europe is the second largest market in the world due to high income and healthcare penetration.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing industrial sector during the forecast period.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.
Key Players in the Global Optic Nerve Glioma Market
Some of key players profiled in the report are Emcure Pharmaceuticals ltd., Sigma-Aldrich Co., Thermo Fisher Scientific Inc., Pfizer Inc., Taj Pharmaceuticals Limited, Novartis International AG, Teva Pharmaceutical Industries Ltd, GE Healthcare, Siemens Healthcare, Philips Healthcare, Shimadzu Corporation, Toshiba Medical Systems Corporation and others.
Detailed Table of Contents for Optic Nerve Glioma Market Research Report - Global Forecast till 2023:
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
...Continued

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com